COLL News and Press, Collegium Pharmaceutical Inc. From 02/24/22

Collegium Pharmaceutical, Inc. (COLL) Q4 2021 Earnings Conference Call February 24, 2022, 04:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations & Corporate Communications Joe Ciaffoni - President, CEO & Director Colleen Tupper - CFO Scott Dreyer - Chief Commercial...

Collegium Pharmaceutical press release (NASDAQ:COLL): Q4 GAAP EPS of -$0.73 misses by $1.08. Revenue of $27.36M (-64.1% Y/Y) misses by $54.17M. 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER. Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITD...

The following slide deck was published by Collegium Pharmaceutical, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Collegium Pharmaceutical, Inc. 2021 Q4 - Results - Earnings Call Presentation

– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million – &#x...

Intel to acquire Tower Semiconductor for $53 a share, representing a premium of almost 60% to Tower's closing price the previous day. Madison Dearborn Partners to acquire MoneyGram International for $11 per share, representing a premium of approximately 50% to MoneyGram’s unaff...

Collegium Pharmaceutical has seen a decent 2021, but starts 2022 with a big and interesting deal. Investors are highly attracted to diversification and in anticipation of huge synergies. This looks compelling, yet the earnings situation will likely become complicated for quite a w...

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

Collegium Pharmaceutical is acquiring BioDelivery Sciences for $5.60 per share in an all cash offer. I argue why the deal is good, but not great for BioDelivery Sciences. We take a cursory look at Collegium Pharmaceutical. For further details see: BioDelivery Sciences Bu...

Worries about Ukraine and Federal Reserve policy led to an uncertain session on Monday, with the Dow and S&P 500 posting modest losses. The Nasdaq finished the day just below the unchanged mark. While the overall market failed to find significant buying interest, electric vehicle stocks m...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the biggest movers in today’s market is BioDelivery Sciences (NASDAQ: BDSI ). At the time of writing, BDSI stock has surged more than 50% higher on incredible volume. This move comes, as many would expec...